Adoption of Financial Reporting Standard (FRS) 101

Premaitha Health plc

("Premaitha" or "the Company")

Adoption of Financial Reporting Standard (FRS) 101

Manchester, UK - 22 June 2016: Premaitha Health plc (AIM: NIPT), announces that following the publication of FRS 100 'Application of Financial Reporting Requirements' by the Financial Reporting Council, the Company is required to change the accounting framework for its own financial statements, and those of its UK subsidiary Premaitha Ltd, which currently adopt United Kingdom Generally Accepted Accounting Standards (UK GAAP). It is intended for the year ended 31 March 2016 and future years that the parent entity adopts FRS 101 'Reduced Disclosure Framework', based on International Financial Reporting Standards (IFRS) as adopted by the European Union.

The Group's consolidated financial statements are unaffected by this change, and will continue to be prepared in accordance with International Financial Reporting Standards (IFRSs) as adopted by the European Union. The adoption of FRS 101 does not require restatement of comparative year amounts and there are no material changes to the presentation of Company's own financial statements compared to prior year.

Objections to the use of the disclosure exemptions may be served by a shareholder or shareholders holding in aggregate 5% or more of the total allotted shares of the Company in writing to Barry Hextall, Chief Financial Officer, at Premaitha Health, Rutherford House, Manchester Science Park, Manchester, M15 6SZ by not later than 12 July 2016.

For more information, please contact:

About Premaitha:

Premaitha is a molecular diagnostics company which uses the latest advances in DNA analysis technology to develop safer, faster and regulatory approved non-invasive screening tests for pregnant women.

Premaitha's lead test - the IONA® test - was launched in February 2015 and is the leading CE marked complete system which estimates the risk of a fetus being affected with Down's syndrome or other genetic conditions. The IONA® test is performed on the mother's blood sample - which contains traces of fetal DNA - and then analysed using next generation DNA sequencing technology from ThermoFisher Scientific.

Unlike existing prenatal screening methods, due to its speed and high level of accuracy, the IONA® test can significantly reduce the number of women subjected to unnecessary invasive follow up diagnostic procedures which carry a risk of miscarriage.

NIPT is an emerging, multi-billion dollar global market and Premaitha's complete CE Marked system enables laboratories and health care practitioners to offer an approved, non-invasive prenatal screening solution in-house.

Premaitha is based in Manchester Science Park, United Kingdom and its shares trade on the AIM market of the London Stock Exchange (AIM: NIPT). For further information please visit www.premaitha.com. Follow us on twitter @PremaithaHealth.